JP5802868B2 - マクロファージ遊走阻止因子の阻害作用に基づく疾患の治療剤 - Google Patents

マクロファージ遊走阻止因子の阻害作用に基づく疾患の治療剤 Download PDF

Info

Publication number
JP5802868B2
JP5802868B2 JP2015527333A JP2015527333A JP5802868B2 JP 5802868 B2 JP5802868 B2 JP 5802868B2 JP 2015527333 A JP2015527333 A JP 2015527333A JP 2015527333 A JP2015527333 A JP 2015527333A JP 5802868 B2 JP5802868 B2 JP 5802868B2
Authority
JP
Japan
Prior art keywords
benzopyran
amino
phenoxy
oxo
mif
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015527333A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2015008827A1 (ja
Inventor
田中　啓一
啓一 田中
貴美子 森本
貴美子 森本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyama Chemical Co Ltd
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Priority to JP2015527333A priority Critical patent/JP5802868B2/ja
Application granted granted Critical
Publication of JP5802868B2 publication Critical patent/JP5802868B2/ja
Publication of JPWO2015008827A1 publication Critical patent/JPWO2015008827A1/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
JP2015527333A 2013-07-18 2014-07-17 マクロファージ遊走阻止因子の阻害作用に基づく疾患の治療剤 Expired - Fee Related JP5802868B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2015527333A JP5802868B2 (ja) 2013-07-18 2014-07-17 マクロファージ遊走阻止因子の阻害作用に基づく疾患の治療剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2013149690 2013-07-18
JP2013149690 2013-07-18
PCT/JP2014/069026 WO2015008827A1 (ja) 2013-07-18 2014-07-17 マクロファージ遊走阻止因子の阻害作用に基づく疾患の治療剤
JP2015527333A JP5802868B2 (ja) 2013-07-18 2014-07-17 マクロファージ遊走阻止因子の阻害作用に基づく疾患の治療剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015167851A Division JP6060231B2 (ja) 2013-07-18 2015-08-27 マクロファージ遊走阻止因子の阻害作用に基づく疾患の治療剤

Publications (2)

Publication Number Publication Date
JP5802868B2 true JP5802868B2 (ja) 2015-11-04
JPWO2015008827A1 JPWO2015008827A1 (ja) 2017-03-02

Family

ID=52346269

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015527333A Expired - Fee Related JP5802868B2 (ja) 2013-07-18 2014-07-17 マクロファージ遊走阻止因子の阻害作用に基づく疾患の治療剤
JP2015167851A Active JP6060231B2 (ja) 2013-07-18 2015-08-27 マクロファージ遊走阻止因子の阻害作用に基づく疾患の治療剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015167851A Active JP6060231B2 (ja) 2013-07-18 2015-08-27 マクロファージ遊走阻止因子の阻害作用に基づく疾患の治療剤

Country Status (22)

Country Link
US (3) US20150353519A1 (enExample)
EP (2) EP3078372B1 (enExample)
JP (2) JP5802868B2 (enExample)
CN (1) CN105407887B (enExample)
AU (1) AU2014291149B2 (enExample)
CA (1) CA2918325C (enExample)
CY (2) CY1118140T1 (enExample)
DK (2) DK3078372T3 (enExample)
ES (2) ES2642440T3 (enExample)
HR (2) HRP20161317T1 (enExample)
HU (2) HUE034661T2 (enExample)
IL (1) IL243550B (enExample)
LT (2) LT2929880T (enExample)
NO (1) NO3078372T3 (enExample)
PL (2) PL2929880T3 (enExample)
PT (2) PT2929880T (enExample)
RS (2) RS55394B1 (enExample)
RU (2) RU2750540C2 (enExample)
SI (2) SI2929880T1 (enExample)
SM (3) SMT201700080T1 (enExample)
TW (1) TWI603965B (enExample)
WO (1) WO2015008827A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018137708A1 (zh) * 2017-01-26 2018-08-02 重庆莱美药业股份有限公司 一种纳米炭-铁复合体系及其组合物、制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023714A1 (fr) * 1993-04-09 1994-10-27 Toyama Chemical Co., Ltd. Immunomodulateur, inhibiteur de l'adherence cellulaire, et agent permettant de traiter et de prevenir des maladies auto-immunes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753725B2 (ja) * 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
WO1997023714A1 (de) * 1995-12-21 1997-07-03 Siemens Aktiengesellschaft Luftansaugvorrichtung mit variabler saugrohrlänge für eine brennkraftmaschine
DE10044091A1 (de) * 2000-09-07 2002-04-04 Merck Patent Gmbh Chromanonderivate
GB0507696D0 (en) * 2005-04-15 2005-05-25 Novartis Ag Organic compounds
GB0507695D0 (en) 2005-04-15 2005-05-25 Novartis Ag Organic compounds
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
BR112014002407A2 (pt) 2011-08-30 2017-02-21 Toyama Chemical Co Ltd método para melhorar a terapia contra doenças autoimunes tais como artrite reumatóide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023714A1 (fr) * 1993-04-09 1994-10-27 Toyama Chemical Co., Ltd. Immunomodulateur, inhibiteur de l'adherence cellulaire, et agent permettant de traiter et de prevenir des maladies auto-immunes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6014042814; 'Ｐｈａｒｍａｃｏｌｏｇｉｃａｌ　Ｓｔｕｄｉｅｓ　ｏｎ　３-Ｆｏｒｍｙｌａｍｉｎｏ-７-ｍｅｔｈｙｌｓｕｌｆｏｎｙｌａｍｉｎｏ-６-ｐｈｅｎｏｘｙ-４Ｈ-１-ｂｅｎｚｏｐｙｒａｎ-４-ｏｎｅ　（Ｔ-６１' Ｊ　Ｐｈａｒｍａｃｏｂｉｏ　Ｄｙｎ Ｖｏｌ．１５，　Ｎｏ．１１, 1992, Ｐａｇｅ．６４１-６４７ *
JPN6014042817; 'Ｓｙｎｔｈｅｓｉｓ　ａｎｄ　ｂｒａｄｙｋｉｎｉｎ　ｉｎｈｉｂｉｔｏｒｙ　ａｃｔｉｖｉｔｙ　ｏｆ　ｎｏｖｅｌ　ｎｏｎ-ｐｅｐｔｉｄｅ　ｃｏｍｐｏｕｎｄｓ，　ａｎｄ　ｅｖａｌｕａｔｉｏｎ　ｏｆ　ｉｎ　ｖｉ' Ｂｉｏｏｒｇａｎｉｃ　＆　ｍｅｄｉｃｉｎａｌ　ｃｈｅｍｉｓｔｒｙ， Ｖｏｌ．　１８，　Ｎｏ．　６, 2010, ｐｐ．２３２７-３６ *
JPN6014042820; 'Ａ　ｎｅｗ　ａｎｔｉ-ｒｈｅｕｍａｔｉｃ　ｄｒｕｇ，　Ｔ-６１４，　ｅｆｆｅｃｔｉｖｅｌｙ　ｓｕｐｐｒｅｓｓｅｓ　ｔｈｅ　ｄｅｖｅｌｏｐｍｅｎｔ　ｏｆ　ａｕｔｏｉｍｍｕｎｅ　ｅｎｃｅｐｈａｌｏｍｙｅｌ' Ｊｏｕｒｎａｌ　ｏｆ　Ｎｅｕｒｏｉｍｍｕｎｏｌｏｇｙ Ｖｏｌ．８９，Ｎｏ．１，２, 1998, ｐ．３５-４２ *
JPN6014042823; 'ラット実験的自己免疫性脳脊髄炎に対する抗リウマチ薬，Ｔ-６１４の抑制作用' 日本免疫学会総会・学術集会記録 Ｖｏｌ．２５, 1995, Ｐａｇｅ．３１５ *
JPN6014042827; 'Ｒｏｌｅ　ｏｆ　ＩＬ-１　ａｎｄ　ｐｏｔｅｎｔｉａｌ　ｔｈｅｒａｐｉｅｓ　ｉｎ　ｍｕｌｔｉｐｌｅ　ｓｃｌｅｒｏｓｉｓ．' Ｄｒｕｇ　Ｄｉｓｃｏｖｅｒｙ　Ｔｏｄａｙ：　Ｔｈｅｒａｐｅｕｔｉｃ　Ｓｔｒａｔｅｇｉｅｓ Ｖｏｌ．　４，　Ｎｏ．　１, 2007, ｐｐ．１９-２４． *

Also Published As

Publication number Publication date
CA2918325C (en) 2018-06-26
RS55394B1 (sr) 2017-04-28
SMT201700080B (it) 2017-03-08
WO2015008827A1 (ja) 2015-01-22
SMT201700080T1 (it) 2017-03-08
EP3078372B1 (en) 2017-09-13
PL3078372T3 (pl) 2018-02-28
LT2929880T (lt) 2016-11-25
SI2929880T1 (sl) 2016-12-30
US9918963B2 (en) 2018-03-20
CY1118140T1 (el) 2017-06-28
AU2014291149A1 (en) 2016-02-11
EP2929880A1 (en) 2015-10-14
RU2750540C2 (ru) 2021-06-29
EP2929880A4 (en) 2015-10-14
US20160228404A1 (en) 2016-08-11
ES2642440T3 (es) 2017-11-16
AU2014291149B2 (en) 2017-05-04
DK3078372T3 (en) 2017-10-16
DK2929880T3 (da) 2017-01-02
HRP20161317T1 (hr) 2016-12-16
HUE029800T2 (en) 2017-04-28
TW201536764A (zh) 2015-10-01
PT2929880T (pt) 2016-11-08
HUE034661T2 (en) 2018-02-28
EP2929880B1 (en) 2016-09-14
US20150353519A1 (en) 2015-12-10
EP3078372A1 (en) 2016-10-12
PT3078372T (pt) 2017-10-18
IL243550B (en) 2019-06-30
CN105407887A (zh) 2016-03-16
CA2918325A1 (en) 2015-01-22
HK1222556A1 (zh) 2017-07-07
JP6060231B2 (ja) 2017-01-11
CN105407887B (zh) 2018-09-04
SI3078372T1 (en) 2018-01-31
US20160228406A1 (en) 2016-08-11
ES2593527T3 (es) 2016-12-09
RU2641301C2 (ru) 2018-01-17
SMT201700606T1 (it) 2018-01-11
NO3078372T3 (enExample) 2018-02-10
RU2017131951A (ru) 2019-02-06
TWI603965B (zh) 2017-11-01
HRP20171497T1 (hr) 2017-11-17
IL243550A0 (en) 2016-02-29
LT3078372T (lt) 2017-11-27
RU2017131951A3 (enExample) 2020-12-18
RU2016105141A (ru) 2017-08-23
CY1119496T1 (el) 2018-03-07
JP2016034953A (ja) 2016-03-17
PL2929880T3 (pl) 2017-03-31
RS56489B1 (sr) 2018-01-31
JPWO2015008827A1 (ja) 2017-03-02

Similar Documents

Publication Publication Date Title
JP6589251B2 (ja) グルタルイミド誘導体を含む医薬組成物、及び好酸球性疾患を処置するためのその適用
US8685392B2 (en) Rothia species glutamine endopeptidases and use thereof
CN101820848B (zh) 抑制n-酰基乙醇胺水解性酸酰胺酶的组合物和方法
KR102362277B1 (ko) 면역조절제로서 1,2,4-옥사디아졸 유도체
TW201927782A (zh) 作為C5aR抑制劑之經二芳基取代之6,5-稠合環化合物
ES2676194T3 (es) Método para activar células T reguladoras con agonistas de receptor adrenérgico alfa 2B
KR20170084067A (ko) C-c 케모카인 수용체 타입 9 (ccr9)의 억제제 및 항-알파4베타7 인테그린 차단 항체의 조합 요법
US20230129151A1 (en) Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
JP2005532380A (ja) アラニルアミノペプチダーゼの阻害剤の使用および該阻害剤を含む薬学的配合物
JP2024531259A (ja) 免疫不寛容を軽減し、自己免疫障害を治療するための組成物及び方法
JP2003508512A (ja) 非ペプチド性サイクロフィリン結合化合物とその用途
JP6060231B2 (ja) マクロファージ遊走阻止因子の阻害作用に基づく疾患の治療剤
PT2120919E (pt) Nova combinação para utilização no tratamento de perturbações inflamatórias
WO2005115397A2 (en) Compositions and treatments for modulating kinase and/or hmg-coa reductase
HK1222556B (en) Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor
WO2019213302A1 (en) Treating friedreich's ataxia with dimethyl fumarate
JPH10330258A (ja) 好酸球活性化抑制剤
AU3266099A (en) Inflammatory cell inhibitors

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150831

R150 Certificate of patent or registration of utility model

Ref document number: 5802868

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees